European Archives - Page 763 of 1390 - European Medical Journal

Setting the stage for a more equitable future

The ambition of the Healthcare Businesswomen’s Association is to drive change in diversity, equity and inclusion healthcare and life sciences. Read the article to find out how.

Time to turn to TikTok?

TikTok took younger generations by storm in 2021. Is it time for pharma to turn to the platform? Read the article to find out more.

Varicella Zoster Reactivation Following mRNA Vaccination: Two Case Reports and a Review of Cutaneous Adverse Events of COVID-19 Vaccines

Varicella Zoster reactivation and cutaneous reaction as a mRNA vaccine side effect following COVID 19 vaccination…

Boehringer and Lilly target heart health equality

Boehringer Ingelheim and Eli Lilly launch health initiative supporting women with heart failure to drive equality.

Getting into gamification

While the pharma industry is far away from immersing patients and HCPs in an open world of role play games, extended use of gamification is certainly on the horizon. FInd out more.

Sanofi to adopt “race-like mindset” with F1 collab

Sanofi and McLaren Racing join forces to improve drug manufacturing efficiency and R&D. Read now for more details.

High Opioid Use Before Total Knee Arthroplasty

Insights into high rates of opioid use, specifically in patients with osteoarthritis (OA) before undergoing total knee arthroplasty…

Imaging Shows Importance of Weight Change in Knee Osteoarthritis

Which showed that weight gain could worsen the damage of knee OA, as demonstrated through biomedical imaging…

Can You Trust Your Gut?

Johnathan and Dr Oliver Grundmann discuss their opinions on the use of vitamins, and how the gut microbiota and central nervous system are connected.

Social Impacts and Quality of Life in Patients with β-Thalassaemia

My selection for this issue is the article ‘Social Impact and Quality of Life of Patients with β-Thalassemia: A Systematic Review’ by Greco and Marino. Quality of life is becoming more and more important in the evaluation of clinical trials, and also by regulatory authorities, particularly in chronic diseases (which can be seen by the U.S. Food and Drug Administration’s [FDA] recent position on luspatercept). Therefore, understanding its meaning and limitations is very important.